Latest news
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development - PharmaDispatchPharmaDispatch · Mon, 10 Aug 2026 03:02:54 GMTPercheron Therapeutics (ASX:PER): Why Is Clinical Progress in Focus? - Kalkine MediaKalkine Media · Mon, 10 Aug 2026 02:26:00 GMTPercheron Therapeutics Says James Garner To Step Down As CEO And Managing Director - TradingViewTradingView · Mon, 10 Aug 2026 01:41:00 GMTPercheron Therapeutics names Michael Baker CEO as James Garner moves to non-executive role - TipRanksTipRanks · Sun, 09 Aug 2026 22:43:56 GMTPercheron Therapeutics Phase II progress highlighted by Edison with 5.5-cent valuation - Proactive financial newsProactive financial news · Wed, 05 Aug 2026 01:05:34 GMTPercheron Advances Lead Cancer Drug Minperstobart and Raises $2.2m for New Trial - TipRanksTipRanks · Mon, 03 Aug 2026 04:08:18 GMTPercheron Therapeutics Cash Balance Rises to $4.05 Million as HMBD-002 Gains WHO Name 'Minperstobart' - KalkineKalkine · Fri, 31 Jul 2026 07:00:00 GMTPercheron Therapeutics targets clinical return for HMBD-002 after productive June quarter - Proactive financial newsProactive financial news · Fri, 31 Jul 2026 00:48:00 GMT